02-11-2019 01:27 PM CET - Advertising, Media Consulting, Marketing Research
Print

DNA Vaccines Market by Type, Technology, Disease indication, Route of administration, End user and Geography. Key Players are Merck & Co., Inc. (U.S.), Sanofi Pasteur SA (France), Astellas Pharma Inc. (Japan), GlaxoSmithKline, plc (U.K.), Pfizer, Inc. (U.

Press release from: Precision Business Insights
Precision Business Insights (PBI) in its report titled “DNA Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The DNA vaccine market size was accounted for US$ XX Mn in 2018 and anticipated to account for US$ XX Mn by 2025. Increased prevalence of infectious diseases and increasing number of antibiotic resistant pathogen will create a demand for the DNA vaccine market. The rapid developments in the DNA synthesis, immunobiology, and molecular biology is the major factor anticipated the drive the growth of the DNA vaccines market. However, the strict government regulations are likely to hinder the growth of the DNA vaccines market.

DNA vaccine market segmented on the basis of vaccine type, technology, diseases indication, route of administration, and end users.

Recombinant Vaccines Segment Expected to Dominate the Market

Based on technology the DNA vaccine market is segmented into recombinant vaccines, inactivated and subunit vaccines, conjugate vaccines, toxoid vaccines and live attenuated vaccines. Recombinant vaccines are expected to dominate the DNA vaccine market growth due to the presence of high number of recombinant protein vaccines in the market.

Human Vaccines Projected to Accounts for Large Revenue Share.

Based on end-user type, the DNA vaccine is segmented into human vaccine, animal vaccines and research application. The majority of DNA vaccines available in the market are targeted for humans, hence human vaccines are expected to dominate the revenue share. Moreover, the strong pipeline of human targeted vaccines is likely to aid the market growth.

Read more Insights at precisionbusinessinsights.com/market-reports/dna-vaccines...

North America, Accounts for Major Revenue Share for DNA Vaccine Market

Precision Business Insights (PBI), DNA vaccine market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional analysis, North America accounted for major revenue share due to the adoption of novel vaccines in the region. The awareness about the modern treatment methods among the healthcare fraternity is anticipated to drive the growth of the market in this region. Following the North American region are the regions of Europe and Asia Pacific are exhibiting significant revenue growth. The Asia Pacific is expected to show rapid growth over the forecasted period.

Strategic Approaches and Product Launch Play Vital Role in DNA Vaccine Market

Market strategies such as new product launch and approaches play an important role in the development of the market. For instances, in 2006, Merck (together with its European partner, Sanofi Pasteur) launched its cervical cancer vaccine, Gardasil. The success of this vaccine, and its second-in-line competitor, Cervarix (GSK), marked a milestone in the vaccine industry. The products competed in an entirely new vaccine market for prevention of a specific cancer, precancerous genital lesions, and genital warts due to the human papillomavirus (HPV). In 2005 the first DNA vaccine to be approved was the equine West Nile virus vaccine.

Request Sample Brochure of the Report at precisionbusinessinsights.com/request-sample?product_id=2...

Key players in the market include Merck & Co., Inc. (U.S.), Sanofi Pasteur SA (France),Astellas Pharma Inc. (Japan), GlaxoSmithKline, plc (U.K.),Pfizer, Inc. (U.S), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Panacea Biotec (India), Protein Sciences Corporation (U.S),Bavarian Nordic (Denmark).

Detailed Segmentation

By Vaccine Type

o Monovalent Vaccines
o Multivalent Vaccines

By Technology

o Recombinant Vaccines
o Inactivated and Subunit Vaccines
o Conjugate Vaccines
o Toxoid Vaccines
o Live Attenuated Vaccines

By Diseases Indication

o Human Papilloma Virus (HPV)
o Pneumococcal Disease
o Influenza
o Meningococcal Disease
o MMR (measles, mumps, and rubella)
o Dengue
o Polio
o Others

By Route of Administration

o Oral
o Parental
o Others

By End Users

o Human Health
o Animal Health
o Research Application

Geography

o North America
 U.S.
 Canada
o Europe
 Germany
 UK
 France
 Russia
 Spain
 Italy
 Rest of Europe
o Asia-Pacific
 China
 Japan
 India
 ASEAN
 Rest of Asia Pacific
o Latin America
 Brazil
 Mexico
 Argentina
 Chile
 Rest of Latin America
o Middle East and Africa
 South Africa
 Gulf Cooperation Council Countries(GCCC)
 Rest of MEA

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact us
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @www.precisionbusinessinsights.com

This release was published on openPR.
News-ID: 1577022 • Views: 76
More releasesMore releases

You can edit or delete your press release here: